REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot192310.32687/1561-5936-2026-30-2-178-182Original ArticleMethods of comprehensive environmental assessment of pharmaceutical industry facilitiesGolovinAleksei V.avg@vmin.ruPyatigorskayaNathalia V.pyatigorskaya_n_v@staff.sechenov.ruBrkichLiliana L.brkich.lily@gmail.comZyryanovOleg A.zyryanov_o_a@staff.sechenov.ruBelyaevVasiliy V.belyaev_v_v_1@staff.sechenov.ruSechenov First Moscow State Medical University, 119048, Moscow, RussiaPacific State Medical University, 690002, Vladivostok, RussiaN. A. Semashko National Research Institute of Public Health, Moscow, Russia04072026217818207072026Copyright © 2026,2026The article examines current approaches to environmental assessment of pharmaceutical enterprises, taking into account the specific nature of emissions of biologically active substances capable of exerting effects at low concentrations. A sequential assessment framework is analyzed: source ? infrastructure ? wastewater treatment ? receiving ecosystem ? accumulation zones. The need to combine targeted analysis of priority compounds with non-targeted methods, including high-resolution mass spectrometry, is substantiated to ensure comprehensive identification of contaminants. The importance of integrating chemical, biological, and ecotoxicological methods, including the assessment of antimicrobial resistance, is demonstrated. High variability of emissions and the need for long-term monitoring are highlighted. Key principles of a comprehensive, risk-based approach aimed at improving the reliability of environmental impact assessment are formulated.environmental impact of pharmaceutical productionwater pollutiontargeted monitoring methodsэкологическое влияние фармацевтических производствзагрязнение водтаргетные методы мониторинга[Larsson D. G. J. Pollution from drug manufacturing: review and perspectives. Philos. Trans. R. Soc. B Biol. Sci. 2014;369(1656):20130571.][Boxall A. B.A., Rudd M. A., Brooks B. W. et al. Pharmaceuticals and personal care products in the environment. Environ. Health Perspect. 2012;120:1221—1229.][aus der Beek T., Weber F. A., Bergmann A. et al. Pharmaceuticals in the environment—global occurrences and perspectives. Environ. Toxicol. Chem. 2016;35:823—835.][Bengtsson-Palme J., Larsson D. G. J. Antibiotic resistance genes in the environment: prioritizing risks. Nat. Rev. Microbiol. 2015;13:396—408.][Karkman A., Do T. T., Walsh F., Virta M. P. J. Antibiotic-resistance genes in waste water. Trends Microbiol. 2018;26:220—228.][Myasnikov V. M. Influence of medicines on the hydrosphere of the planet. Voprosy Nauki. 2022;(1):57—62. (In Russ.)][Petrie B., Barden R., Kasprzyk-Hordern B. A review on emerging contaminants in wastewaters and the environment. Water Res. 2015;72:3—27.][Fick J., Söderström H., Lindberg R. H. et al. Contamination of surface, ground, and drinking water from pharmaceutical production. J. Hazard. Mater. 2009;170:1128—1133.][Larsson D. G.J., de Pedro C., Paxeus N. Effluent from drug manufacturers contains extremely high levels of pharmaceuticals. J. Hazard. Mater. 2007;148:751—755.][Kuznetsov D. A. Approaches to assessing environmental safety in pharmacy. Vestn. Nov. Med. Tekhnol. 2010;17(4):202—205. (In Russ.)][Hollender J., Schymanski E. L., Singer H. P., Ferguson P. L. Nontarget screening with high resolution mass spectrometry in environmental analysis. Environ. Sci. Technol. 2017;51:11505—11512.][Michael I., Rizzo L., McArdell C. S. et al. Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria. Water Res. 2013;47:957—995.][Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater. Sci. Total Environ. 2012;429:123—155.][Manaia C. M., Rocha J., Scaccia N. et al. Antibiotic resistance in wastewater treatment plants. Water Res. 2018;134:365—376.][Tran N. H., Reinhard M., Gin K. Y. H. Occurrence and fate of emerging contaminants in municipal wastewater treatment plants. Sci. Total Environ. 2018;613—614:1317—1335.][European Medicines Agency. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00 Rev. 1). London; 2006.][Kuznetsov D. A. Ensuring environmental safety of pharmaceutical activities. Industrialnaya Ekonomika. 2020;(2):53—56. (In Russ.)][Kuznetsov D. A. Justification and development of methodology for managing the economic security of pharmaceutical systems. Abstract of D. Pharm. Sci. dissertation. Moscow; 2015. 49 p. (In Russ.)]